Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.